Navigation Links
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
Date:10/24/2013

SAN DIEGO, Oct. 24, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced the pricing of an underwritten public offering of 4,150,000 shares of common stock at an offering price of $7.25 per share.  The shares will begin trading on The NASDAQ Capital Market on October 25, 2013 under the symbol "SRNE." The gross proceeds to Sorrento from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on or about October 30, 2013, subject to customary closing conditions. Sorrento has granted the underwriters a 45-day option to purchase up to an additional 622,500 shares of common stock to cover over-allotments, if any.

Sorrento intends to use the net proceeds received from the offering to fund its research and development activities, including its registrational clinical trial of Cynviloq™, for working capital, other general corporate purposes, and possibly acquisitions of other companies, products or technologies.

In connection with its listing on The NASDAQ Capital Market, Sorrento's common stock will cease trading on the OTC QB.   

Aegis Capital Corp. is acting as the sole book-running manager for this offering.

CRT Capital is acting as co-manager for this offering. 

A shelf registration statement and accompanying base prospectus on Form S-3 relating to the shares was filed with the Securities and Exchange Commission and is effective.  A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's web site at http://www.sec.gov. Copies of the final prospectus supplement, when available, may be obtained from the SEC's web site or the offices of Aegis C
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
2. Sorrento Therapeutics Completes IgDraSol Merger
3. Sorrento Therapeutics to Present at Two Healthcare Conferences
4. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
5. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
8. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... a conference call and audio webcast to discuss financial results ... closes on Thursday, July 31, 2014 at 4:30 p.m. ET. ... Date: July 31, 2014 Time: 4:30 PM ET ... International: (678) 373-0875 A webcast replay will be ...
(Date:7/28/2014)... Calif., July 28, 2014 Anthera Pharmaceuticals, Inc. (NASDAQ: ... update for the second quarter ended June 30, 2014. ... 30, 2014 was $7.3 million, compared to $8.3 million for ... is a direct result of a decrease in interest expense ... the six months ended June 30, 2014 was $15.2 million, ...
(Date:7/28/2014)... Corporation (NASDAQ: LMNX ) today announced financial ... Financial and operating highlights include the following: ... 2 percent increase over the second quarter of 2013. ... a 9 percent increase over the second quarter of ... analyzers, which included 148 LX systems, 96 MAGPIX systems, ...
Breaking Medicine Technology:Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 6Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 7Luminex Corporation Reports Second Quarter 2014 results 2Luminex Corporation Reports Second Quarter 2014 results 3Luminex Corporation Reports Second Quarter 2014 results 4Luminex Corporation Reports Second Quarter 2014 results 5Luminex Corporation Reports Second Quarter 2014 results 6Luminex Corporation Reports Second Quarter 2014 results 7Luminex Corporation Reports Second Quarter 2014 results 8Luminex Corporation Reports Second Quarter 2014 results 9Luminex Corporation Reports Second Quarter 2014 results 10Luminex Corporation Reports Second Quarter 2014 results 11Luminex Corporation Reports Second Quarter 2014 results 12Luminex Corporation Reports Second Quarter 2014 results 13Luminex Corporation Reports Second Quarter 2014 results 14Luminex Corporation Reports Second Quarter 2014 results 15Luminex Corporation Reports Second Quarter 2014 results 16Luminex Corporation Reports Second Quarter 2014 results 17
... PRGO ; TASE) today announced results for its ... and CEO Joseph C. Papa commented, "We are very pleased ... contributors to this strong performance were $44 million of new ... segments and another solid quarter in Nutritionals. In Consumer Healthcare, ...
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today ... at the Bank of America Merrill Lynch Healthcare conference in Las ... Vegas, NV Presentation date: Tuesday May 10, 2011 ... A live webcast and 30-day archive of this presentation will ...
Cached Medicine Technology:Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 2Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 3Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 4Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 5Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 6Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 7Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 8Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 9Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 10Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 11Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 12Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 13Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 14Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 15Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 16Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 17Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 18
(Date:7/28/2014)... Cancer cells are gluttons. We have long known that ... became clear that some tumor cells are also characterized ... unlikeliness to join in an ordered set. Researchers are ... metastasis. , At EPFL, Etienne Meylan,s research team was ... for sugar and mesenchymal behavior result from the ...
(Date:7/28/2014)... Ticket Down is a reputable source ... between Manchester City and Liverpool FC at Yankee Stadium ... countless big events since it opened several years ago. It ... Yankee Stadium, however, it has been a popular destination for ... , The Yankees Stadium is the home of the ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A January ... reduction of gluten intake in those who were self-diagnosed ... Mittry, director of nutrition for San Diego health and ... various gluten considerations for those who are unclear about ... explains that gluten is a protein, found in wheat, ...
(Date:7/28/2014)... 2014 Dawn Echols’ professional background ... and music. This experience has honed her people ... psychology. Her professional counseling ( http://dawningphoenix.com ) work ... for offenders in domestic violence. , As ... she enjoys counseling individuals and groups for a ...
(Date:7/28/2014)... Ticket Down is reliable source ... Dallas, TX at the Cotton Bowl. The 2014 Guinness ... and it is an eight team tourney. The tournament ... teams from La Liga, Serie A, English Premier League, and ... out on the pitch include: Manchester United, Manchester City, ...
Breaking Medicine News(10 mins):Health News:Cancer: Tumors absorb sugar for mobility 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 3Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3
... increase lowers chance of hospitalization or death , ... heart failure, high doses of the drug losartan, an ... and death, a new study shows. , Though ARBs ... study focused on whether dose level makes a difference. ...
... what women should do about the new guidelines, , WEDNESDAY, ... force recommended that women wait until they,re 50 to get ... swift. , Critics such as the American Cancer Society vowed ... age 40 for women of average risk. The American ...
... ... the AnnArbor.com Business Review awarded the company top honors in the Healthcare category during ... ongoing commitment to the local community and recent completion of a $3.6 million expansion ... ...
... Apieron, Inc. has asked the court presiding over ... to raise additional grounds for invalidating Aerocrine,s broadest patent ... , In its motion, Apieron alleges that recently obtained ... Alving, Jan Lundberg, and Edward Weitzberg, inventors named on ...
... , SYDNEY, Nov. 18 Members of the Church ... Ambassadors were out in force Sunday, November 15, distributing thousands ... purpose: to inform kids of the truth about drugs so ... a new drug called Mephedrone, or "MM-Cat," that Sydney students ...
... ... a KTRK-TV, a local television news affiliate, is bringing to light a new technique ... the recovery process and the aesthetic results for patients who undergo surgical treatment for ... ...
Cached Medicine News:Health News:Heart Failure Drug May Help More in Higher Doses 2Health News:Mammography: What to Do Now? 2Health News:Mammography: What to Do Now? 3Health News:Mammography: What to Do Now? 4Health News:Terumo Heart, Inc. Wins Top Healthcare Category Honors at AnnArbor.com's 5th Annual ‘Deals Of The Year' Award Ceremony 2Health News:Terumo Heart, Inc. Wins Top Healthcare Category Honors at AnnArbor.com's 5th Annual ‘Deals Of The Year' Award Ceremony 3Health News:Scientology Volunteers Attack Drug Abuse in Sydney 2Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 2Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 3Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: